Modality
Cell Therapy
MOA
SHP2i
Target
Aβ
Pathway
RNA Splicing
DMDFSGSNB
Development Pipeline
Preclinical
~May 2021
→ ~Aug 2022
Phase 1
~Nov 2022
→ ~Feb 2024
Phase 2
May 2024
→ Oct 2026
Phase 2Current
NCT07887260
1,958 pts·DMD
2024-05→2026-10·Terminated
1,958 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-136mo awayPh2 Data· DMD
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2026-10-13 · 6mo away
DMD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07887260 | Phase 2 | DMD | Terminated | 1958 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Doxacagene | Sanofi | Approved | PSMA | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn |